Laurie Stelzer

CIK: 0001644348

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)8 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

SION

Sionna Therapeutics, Inc.

Director

PMVP

PMV Pharmaceuticals, Inc.

Director

MBX

MBX Biosciences, Inc.

Director

SYRE

Spyre Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

SION
Sionna Therapeutics, Inc.
Jun 17, 2026
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
17.3K shares-
PMVP
PMV Pharmaceuticals, Inc.
Jun 4, 2026
Award(A)
Stock Option (right to buy)
Direct
42K shares-
MBX
MBX Biosciences, Inc.
Jun 4, 2026
Award(A)
Stock option (right to buy)
Direct
12.5K shares-
SYRE
Spyre Therapeutics, Inc.
May 27, 2026
Award(A)
Stock Option (Right to Buy)
Direct
8K shares-
MBX
MBX Biosciences, Inc.
Jan 20, 2026
Award(A)
Stock option (right to buy)
Direct
32K shares-
SION
Sionna Therapeutics, Inc.
Jun 12, 2025
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
20K shares-
PMVP
PMV Pharmaceuticals, Inc.
Jun 5, 2025
Award(A)
Stock Option (right to buy)
Direct
33.5K shares-
SYRE
Spyre Therapeutics, Inc.
May 29, 2025
Award(A)
Stock Option (Right to Buy)
Direct
25K shares-

		Type	Shares	Price		Ownership
Jun 17, 2026	SION Sionna Therapeutics, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	17,340	-	-	Direct
Jun 4, 2026	PMVP PMV Pharmaceuticals, Inc.	Award(A) Stock Option (right to buy)	42,000	-	-	Direct
Jun 4, 2026	MBX MBX Biosciences, Inc.	Award(A) Stock option (right to buy)	12,500	-	-	Direct
May 27, 2026	SYRE Spyre Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	8,026	-	-	Direct
Jan 20, 2026	MBX MBX Biosciences, Inc.	Award(A) Stock option (right to buy)	32,000	-	-	Direct
Jun 12, 2025	SION Sionna Therapeutics, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	19,959	-	-	Direct
Jun 5, 2025	PMVP PMV Pharmaceuticals, Inc.	Award(A) Stock Option (right to buy)	33,500	-	-	Direct
May 29, 2025	SYRE Spyre Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	25,000	-	-	Direct

1-8 of 8 transactions

About Stelzer Laurie

Stelzer Laurie (SEC CIK 0001644348) files insider reports with the SEC as Director of Sionna Therapeutics, Inc. (SION), Director of PMV Pharmaceuticals, Inc. (PMVP) and Director of MBX Biosciences, Inc. (MBX). Signal8 also holds filings tied to 1 other company.

Signal8 holds 10 ownership filings by Stelzer Laurie (2 Form 3, 8 Form 4), filed between Feb 6, 2025 and Jun 18, 2026. Those filings report 8 transactions, from May 29, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Stelzer Laurie's filings is in CARMEL, IN.

Recent filings by Stelzer Laurie

Jun 17, 2026: Grant or award of SION derivative securities (Form 4, code A).
Jun 4, 2026: Grant or award of PMVP derivative securities (Form 4, code A).
Jun 4, 2026: Grant or award of MBX derivative securities (Form 4, code A).
May 27, 2026: Grant or award of SYRE derivative securities (Form 4, code A).
Jan 20, 2026: Grant or award of MBX derivative securities (Form 4, code A).

Other insiders filing for Sionna Therapeutics, Inc. (SION)

RA CAPITAL MANAGEMENT, L.P., Director
Ridloff Elena, CFO and CBO
McKee Charlotte, CMO and Head of R&D
Fitzpatrick Jennifer, CLO and Head of Program Mgmt.
Cloonan Michael, President & CEO
Thompson Peter A., Director

How to read Form 4 transaction codes